Profit Metrics Summary (Annual)
According to GSK plc's latest annual financial reports:
- The company has reported a gross profit of 22.33B, indicating the amount earned after deducting the cost of goods sold (COGS) from revenue. The gross profit margin is 71.16%, with a year-over-year growth of 2.60%.
- GSK plc's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 6.67B. The EBITDA margin stands at 21.25%, showing a growth of -27.03% compared to the previous year.
- The operating income, representing the profit from business operations before taxes and interest, stands at 4.02B. The operating margin is 12.82%, with a year-over-year growth of -40.39%.
- The net income, which shows the company's total earnings or profit after all expenses, is 2.58B. The net profit margin is 8.21%, demonstrating a growth of -47.75% from the previous year.
These metrics provide a comprehensive overview of GSK plc's profitability and operational efficiency over the past year.
Gross Profit
$22.33B
Gross Profit Margin (2023)
71.16%
EBITDA
$6.67B
EBITDA Margin
21.25%
Operating Income (2023)
$4.02B
Operating Margin
12.82%
Net Income
$2.58B
Net Profit Margin
8.21%
Historical Gross Profit
Historical Gross Profit Margin
Historical Gross Profit Growth
Historical EBITDA
Historical EBITDA Margin
Historical EBITDA Growth
Historical Operating Income
Historical Operating Profit Margin
Historical Operating Income Growth
Historical Net Income
Historical Net Profit Margin
Historical Net Income Growth
GSK plc Historical Profit Metrics
GSK plc Historical Profits
The table below shows various profit metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | Gross Profit | Gross Profit Growth | Operating Income | Operating Income Growth | Net Income | Net Income Growth | EBITDA | EBITDA Growth |
|---|---|---|---|---|---|---|---|---|
| 2024 | $22.33B | 2.60% | $4.02B | -40.39% | $2.58B | -47.75% | $6.67B | -27.03% |
| 2023 | $21.76B | 10.08% | $6.75B | 4.85% | $4.93B | 0.14% | $9.14B | 5.90% |
| 2022 | $19.77B | -12.18% | $6.43B | 3.74% | $4.92B | 12.22% | $8.63B | 11.26% |
| 2021 | $22.51B | 0.52% | $6.20B | -20.33% | $4.38B | -23.73% | $7.76B | -23.68% |
| 2020 | $22.39B | 2.30% | $7.78B | 11.81% | $5.75B | 23.77% | $10.16B | 8.38% |
| 2019 | $21.89B | 6.37% | $6.96B | 26.96% | $4.64B | 28.21% | $9.38B | 0.27% |
| 2018 | $20.58B | 3.71% | $5.48B | 34.16% | $3.62B | 136.49% | $9.35B | 8.19% |
| 2017 | $19.84B | 6.69% | $4.09B | 57.31% | $1.53B | 67.98% | $8.64B | 22.39% |
| 2016 | $18.60B | 23.42% | $2.60B | -74.83% | $912.00M | -89.17% | $7.06B | 69.07% |
| 2015 | $15.07B | -3.91% | $10.32B | 186.96% | $8.42B | 205.59% | $4.18B | -23.74% |
| 2014 | $15.68B | -12.48% | $3.60B | -48.82% | $2.76B | -49.30% | $5.48B | -24.73% |
| 2013 | $17.92B | -3.33% | $7.03B | -4.92% | $5.44B | 19.08% | $7.28B | -16.95% |
| 2012 | $18.54B | -7.57% | $7.39B | -5.32% | $4.57B | -13.23% | $8.76B | -12.86% |
| 2011 | $20.05B | -3.58% | $7.81B | 106.37% | $5.26B | 221.97% | $10.05B | 82.07% |
| 2010 | $20.80B | -0.90% | $3.78B | -55.10% | $1.63B | -70.46% | $5.52B | -45.75% |
| 2009 | $20.99B | 17.01% | $8.43B | 17.98% | $5.53B | 17.38% | $10.18B | 19.67% |
| 2008 | $17.94B | 2.44% | $7.14B | -5.95% | $4.71B | -9.63% | $8.51B | -5.75% |
| 2007 | $17.51B | -3.87% | $7.59B | -2.75% | $5.21B | -3.25% | $9.03B | 2.99% |
| 2006 | $18.21B | 7.81% | $7.81B | 13.59% | $5.39B | 14.93% | $8.76B | 591.37% |
| 2005 | $16.90B | 8.13% | $6.87B | 19.42% | $4.69B | 19.98% | $1.27B | -80.83% |
Related Metrics
Explore detailed financial metrics and analysis for GSK.L.